Vitamin D deficiency can result in symptomatic osteomalacia which may cause bone pain and muscle weakness. Two patients with symptomatic osteomalacia after gastric bypass surgery are discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Phosphaturic mesenchymal tumor of the popliteal fossa: a case report and literature review.
Front Oncol
December 2024
Joint Surgery Department, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by hypophosphatemia caused by excessive secretion of fibroblast growth factor-23 (FGF-23) by tumors. This leads to impaired bone mineralization and, ultimately, osteomalacia. The most common underlying cause is a phosphaturic mesenchymal tumor (PMT).
View Article and Find Full Text PDFTumor-Induced Osteomalacia: A Case Report.
Cureus
June 2024
Endocrinology, Diabetes and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, IND.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome with a variable presentation. We present a case of a 55-year-old female who presented with pain in the bilateral hip region for the last two years. On routine biochemical evaluation, she was found to have hypophosphatemia with an X-ray of the bilateral hip region showing an acute stress fracture in the bilateral intertrochanteric region of the femur.
View Article and Find Full Text PDFOncogenic Osteomalacia: Challenges in Diagnosis.
Indian J Surg Oncol
September 2023
Department of Endocrinology, Mazumdar Shaw Cancer Centre, Bengaluru, India.
To report a case of osteomalacia induced by a mesenchymal tumour in the head and neck region, in view of its rarity and classical late diagnosis. To review the literature on the usage of fluorodeoxyglucose-positron emission tomography-computed tomography (FDG PET-CT) and octreotide scanning in the localisation of the culprit tumour. An elderly male presented with a 7-year history of chronic muscle pain and weakness, to the extent of functional disability.
View Article and Find Full Text PDFFGF23 AND ALTERED MINERAL HOMEOSTASIS IN KIDNEY DISEASE AND FOLLOWING INTRAVENOUS IRON.
Trans Am Clin Climatol Assoc
September 2023
Durham, North Carolina.
Fibroblast growth factor 23 (FGF23) is an endocrine hormone that stimulates renal phosphate excretion and suppresses circulating concentrations of 1,25-dihydroxyvitamin D (1,25D). These effects of FGF23 are most evident in rare diseases that are characterized by FGF23-mediated hypophosphatemic rickets-osteomalacia. More commonly, elevated FGF23 is a ubiquitous, early consequence of chronic kidney disease (CKD) in which it helps to maintain normal serum phosphate levels but causes secondary hyperparathyroidism by suppressing 1,25D, and directly promotes cardiovascular disease and death.
View Article and Find Full Text PDFBurosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis.
J Bone Miner Res
November 2023
Kyowa Kirin International, Marlow, UK.
Article Synopsis
- Tumor-induced osteomalacia (TIO) is a rare condition caused by tumors that lower phosphate levels in the body, negatively impacting bone health and overall physical function.
- A phase 2 trial (UX023T-CL201) showed that after 48 weeks of burosumab treatment, patients experienced restored phosphate levels and significant improvements in skeletal health, mobility, and quality of life.
- An analysis of exit interviews from 8 participants indicated that managing pain and fatigue was crucial, with notable improvements reported after treatment, highlighting the importance of patient perspectives on treatment benefits beyond standard measurements.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!